[Federal Register Volume 68, Number 24 (Wednesday, February 5, 2003)]
[Notices]
[Pages 5908-5909]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-2625]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: ``Interleukin-2 Receptor 
and Applications Thereof''

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive license to practice the inventions embodied in U.S. Patent 
No. 5,833,983, entitled ``Interleukin-2 Receptor and Applications 
Thereof,'' to Celltech R&D Ltd., a non-U.S. company with headquarters 
in the United Kingdom.
    The prospective exclusive license territory may be worldwide and 
the field of use may be therapeutics for the treatment of inflammatory 
diseases.

DATES: Only written comments and/or license applications which are 
received by the National Institutes of Health on or before April 7, 
2003 will be considered.

ADDRESSES: Requests for copies of the patent, inquiries, comments and 
other materials relating to the contemplated exclusive license should 
be directed to: Matthew B. Kiser, Technology Licensing Specialist, 
Office of Technology Transfer, National Institutes of Health, 6011 
Executive Boulevard, Suite 325, Rockville, MD 20852-3804. Telephone:

[[Page 5909]]

(301) 435-5236; Facsimile (301) 402-0220; E-mail [email protected].

SUPPLEMENTARY INFORMATION: U.S. Patent No. 5,833,983 relates to the 
field of receptor molecules. Specifically, the technology is related to 
a new polypeptide receptor for interleukin-2, which is a component of 
the high affinity IL-2 receptor, antibodies against this new 
polypeptide and recombinant interleukins capable of binding to the new 
receptor.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, the NIH receives 
written evidence and argument that establish that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: January 28, 2003.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 03-2625 Filed 2-4-03; 8:45 am]
BILLING CODE 4140-01-P